Related Experiment Video
Updated: Aug 28, 2025

In Vitro Microfluidic Disease Model to Study Whole Blood-Endothelial Interactions and Blood Clot Dynamics in Real-Time
Published on: May 24, 2020
Venous thromboembolism in COVID-19: A meta-summary of cases
Naif Saad ALGhasab1, Leen A Altamimi1, Mohammed Salem Alharbi1
1From the Department of Internal Medicine (ALGhasab), Medical Collage, Ha'il University; from the Department of Medicine (Alharbi), College of Medicine, University of Ha'il, Ha'il; from the College of Medicine (Altamimi), King Saud University, Riyadh; from the Department of Surgery (ALMesned), Medical College, Qassim University, Buraydah, Kingdom of Saudi Arabia; and from the Department of Medicine (ALGhasab, Khetan), McMaster University, Canada.
Insights
Venous thromboembolism (VTE), including pulmonary embolism (PE) and deep vein thrombosis (DVT), is a significant concern in COVID-19 patients. Early suspicion and diagnosis are crucial, even in those on anticoagulation, to improve patient outcomes.
Area of Science:
- Medical Research
- Infectious Diseases
- Cardiology
Background:
- Coronavirus disease (COVID-19) has been associated with an increased risk of venous thromboembolism (VTE).
- Understanding the clinical presentation, risk factors, and outcomes of VTE in COVID-19 patients is critical for effective management.
Purpose of the Study:
- To summarize cases of VTE (pulmonary embolism and deep vein thrombosis) in COVID-19 patients.
- To discuss the symptoms, diagnostic methods, clinical features, and prognosis of VTE in this population.
Main Methods:
- A comprehensive literature search was conducted across major databases.
- Studies published between December 1, 2019, and May 5, 2021, were included.
Main Results:
- Twenty-two articles describing 48 COVID-19 patients with VTE were analyzed.
- The majority of patients (79.1%) had pulmonary embolism (PE), and 20.9% had deep vein thrombosis (DVT).
- Comorbidities were common (70.8%), and 85.4% had VTE risk factors; 56.3% received anticoagulation, yet complications occurred in 27.1%.
Conclusions:
- VTE should be suspected in COVID-19 patients, particularly males, the elderly, and those with comorbidities or elevated D-dimer levels.
- VTE must be considered even in patients receiving anticoagulation or presenting with stable disease.
- Prompt diagnosis and management are essential, as 80.4% of patients achieved recovery.
Objectives:
To summarize cases of venous thromboembolism (VTE), including pulmonary embolism (PE) and deep vein thrombosis (DVT) among coronavirus disease (COVID-19) patients and discuss their symptoms, diagnostic method, clinical features, and prognosis.
Methods:
All major databases were searched for relevant studies published between December 1, 2019 and May 5, 2021.
Results:
A total of 233 articles were identified, 22 describing 48 patients were included. A total of 79.1% had PE and 20.9% had DVT. Most patients were men, with a mean age of 56 years. Comorbidities were present in 70.8%, and 85.4% had at least one risk factor of VTE. 56.3% had received anticoagulation therapy. Most patients were treated in the general ward. Complications occurred in 27.1% of the patients, and recovery was achieved in 80.4%.
Conclusion:
Venous thromboembolism must be suspected even in patients who had received prior anticoagulant regimens or in stable cases, especially in males, the elderly, and patients with comorbidities and high D-dimer levels.
Related Concept Videos
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
Venous Thrombosis I: Introduction
Venous Thrombosis III: Interprofessional Care
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
Pulmonary Embolism I: Introduction
Venous Thrombosis IV: Nursing Management

